Biogen Idec Inc.
Records under this name other than patents Biogen Idec Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,608,960 | Method of Purifying Polypeptides by Simulated Moving Bed Chromatography Formerly held In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,198,955 | Method for Reducing Flu-Like Symptoms Associated with Intramuscular Administration of Interferon Using a Fast Titration Escalating Dosing Regimen Formerly held In force · High confidence | In force | High confidence | |
| US 7,759,117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures Formerly held Term ended Term ended Feb 6, 2026 · From the USPTO record | Term ended | Term ended Feb 6, 2026 | From the USPTO record |
| US 7,157,276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures Formerly held Term ended Term ended Jun 21, 2024 · From the USPTO record | Term ended | Term ended Jun 21, 2024 | From the USPTO record |
| US 7,531,174 | Cripto Blocking Antibodies and Uses Thereof Formerly held Term ended Term ended Sep 30, 2023 · Medium confidence | Term ended | Term ended Sep 30, 2023 | Medium confidence |
| US 7,220,356 | Method of Purifying Polypeptides by Simulated Moving Bed Chromatography Formerly held Term ended Term ended Sep 12, 2023 · High confidence | Term ended | Term ended Sep 12, 2023 | High confidence |
| US 7,582,299 | Cripto-Specific Antibodies Formerly held Term ended Ended no later than Aug 31, 2023 · Low confidence | Term ended | Ended no later than Aug 31, 2023 | Low confidence |
| US 7,319,139 | TAG-72 specific CH2 domain deleted antibodies Formerly held Term ended Term ended Jan 29, 2022 · From the USPTO record | Term ended | Term ended Jan 29, 2022 | From the USPTO record |
| US 8,329,172 | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody Formerly held Term ended Term ended Nov 15, 2021 · From the USPTO record | Term ended | Term ended Nov 15, 2021 | From the USPTO record |
| US 7,604,989 | Inhibition of apoptosis process and improvement of cell performance Lapsed on the fee record Ended Oct 20, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 20, 2021 | From the USPTO record |